齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
14期
2040-2042
,共3页
2型糖尿病(T2MD)%非酒精性脂肪性肝病(NAFLD)%血脂%胰岛素抵抗指数(IR)%胰岛素敏感指数(ISI)%罗格列酮(Rosiglitazone)%二甲双胍(Metformin)
2型糖尿病(T2MD)%非酒精性脂肪性肝病(NAFLD)%血脂%胰島素牴抗指數(IR)%胰島素敏感指數(ISI)%囉格列酮(Rosiglitazone)%二甲雙胍(Metformin)
2형당뇨병(T2MD)%비주정성지방성간병(NAFLD)%혈지%이도소저항지수(IR)%이도소민감지수(ISI)%라격렬동(Rosiglitazone)%이갑쌍고(Metformin)
Type 2 Diabetes Mellitus%Nonalcoholic fatty liver disease(NAFLD)%Blood lipid%Insulin resistance(IR)%Insulin sensitivity index(ISI)%Rosiglitazone%Metformin
目的：探讨罗格列酮联合二甲双胍治疗2型糖尿病（ T2MD）并非酒精性脂肪性肝病（ NAFLD）的疗效及对胰岛素抵抗的影响。方法选择我院2011年1月至2014年9月收治的100例T2MD并NAFLD患者，随机分为对照组50例和观察组50例。在卫生宣教、积极控制饮食和合理运动的前提下，观察组：罗格列酮联合二甲双胍，对照组：罗格列酮进行治疗，6月后观察临床疗效、不良反应的发生情况和生化等指标的变化。结果（1）观察组临床总疗效达90．0％，明显优于对照组（72．0％）（ P＜0．05）；在用药期间患者未出现严重的不良反应事件。（2）两组治疗后均有改善糖脂代谢、降酶和减轻胰岛素抵抗的效果（P＜0．05或0．01），但观察组的改善程度较之对照组更明显（P＜0．05或0．01）。结论罗格列酮联合二甲双胍治疗T2MD并NAFLD可显著提高临床疗效，在用药期间无严重不良事件发生，用药安全。并能显著改善糖脂代谢异常、降酶和减低胰岛素抵抗，是治疗T2MD并NAFLD的有效方案，有临床推广应用价值。
目的：探討囉格列酮聯閤二甲雙胍治療2型糖尿病（ T2MD）併非酒精性脂肪性肝病（ NAFLD）的療效及對胰島素牴抗的影響。方法選擇我院2011年1月至2014年9月收治的100例T2MD併NAFLD患者，隨機分為對照組50例和觀察組50例。在衛生宣教、積極控製飲食和閤理運動的前提下，觀察組：囉格列酮聯閤二甲雙胍，對照組：囉格列酮進行治療，6月後觀察臨床療效、不良反應的髮生情況和生化等指標的變化。結果（1）觀察組臨床總療效達90．0％，明顯優于對照組（72．0％）（ P＜0．05）；在用藥期間患者未齣現嚴重的不良反應事件。（2）兩組治療後均有改善糖脂代謝、降酶和減輕胰島素牴抗的效果（P＜0．05或0．01），但觀察組的改善程度較之對照組更明顯（P＜0．05或0．01）。結論囉格列酮聯閤二甲雙胍治療T2MD併NAFLD可顯著提高臨床療效，在用藥期間無嚴重不良事件髮生，用藥安全。併能顯著改善糖脂代謝異常、降酶和減低胰島素牴抗，是治療T2MD併NAFLD的有效方案，有臨床推廣應用價值。
목적：탐토라격렬동연합이갑쌍고치료2형당뇨병（ T2MD）병비주정성지방성간병（ NAFLD）적료효급대이도소저항적영향。방법선택아원2011년1월지2014년9월수치적100례T2MD병NAFLD환자，수궤분위대조조50례화관찰조50례。재위생선교、적겁공제음식화합리운동적전제하，관찰조：라격렬동연합이갑쌍고，대조조：라격렬동진행치료，6월후관찰림상료효、불량반응적발생정황화생화등지표적변화。결과（1）관찰조림상총료효체90．0％，명현우우대조조（72．0％）（ P＜0．05）；재용약기간환자미출현엄중적불량반응사건。（2）량조치료후균유개선당지대사、강매화감경이도소저항적효과（P＜0．05혹0．01），단관찰조적개선정도교지대조조경명현（P＜0．05혹0．01）。결론라격렬동연합이갑쌍고치료T2MD병NAFLD가현저제고림상료효，재용약기간무엄중불량사건발생，용약안전。병능현저개선당지대사이상、강매화감저이도소저항，시치료T2MD병NAFLD적유효방안，유림상추엄응용개치。
Objective To investigate the clinical effect and Insulin resistant influence of Rosiglitazone combined Metformin in patient with Type 2 Diabetes Mellitus ( T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD).Methods 100 patients of T2DM and NAFLD who have been treated in our department from January, 2011 to September, 2014 were randomly divided into control group 50 cases and observation group 50 cases.Under the premise of hygiene education, diet control and reasonable exercise, all patients were treatment with Rosiglitazone and Metformin.Then, we observed the changes of clinical effect, adverse reaction and clinical biochemical indices after 6 months.Results (1) In observation group, the clinical effect was 90.0%which was significantly better than those in control group (72.0%), (P <0.05).Also, there was no severe adverse reaction during treatment course.( 2 ) After treatment, the indices of insulin resistance, glucose and lipid metabolism and enzyme Levels were ameliorated in both 2 groups (P<0.05 or 0.01).In addition, the results of the observation group were much better than control group (P<0.05 or 0.01).Conclusions Treatment with Rosiglitazone and Metformin could significantly increase the clinical effect in the patients with T2DM and NAFLD. Besides, there was no severe adverse reaction during treatment course.In addition, this treatment protocol is safe and could ameliorate insulin resistance, glucose and lipid metabolism and enzyme Levels.Therefore, Treatment with Rosiglitazone and Metformin is an effective protocol and might be popularized to clinical practice.
